|Year : 2017 | Volume
| Issue : 1 | Page : 63-65
Malaria in pregnancy: Is artemisinin-based treatment effective and safe?
Department of General Medicine, Christian Medical College, Vellore, India
|Date of Web Publication||17-Feb-2017|
Department of General Medicine, Christian Medical College, Vellore
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Abraham G. Malaria in pregnancy: Is artemisinin-based treatment effective and safe?. Curr Med Issues 2017;15:63-5
Clinical Question: Which artemisinin.based combination therapy is effective and safe in pregnant women with malaria?
Authorsf conclusion: (1) Artemisinin.based combination therapy is effective and safe in pregnancy, with minimal adverse effects, most of which are reversible. (2) The artemether.lumefantrine combination was associated with acceptable treatment efficacy and minimal adverse events. (3) Dihydroartemisinin.piperaquine was associated with best efficacy and acceptable safety profile.
| The Problem|| |
Malaria in pregnancy is a major public health concern in endemic areas. The problems associated with malaria in a pregnant woman are an increase in the incidence of anemia-complicating pregnancy and low birthweight. In severe cases, it can lead to fetal loss, infant mortality, and maternal death. It becomes imperative, therefore, to treat malaria adequately with effective medicines during pregnancy.
Current treatment guidelines
The World Health Organization guidelines for treatment of malaria in women in the second or third trimester of pregnancy  recommend a 3-day course with either an artemisinin-based combination therapy (ACT) or clindamycin plus a 7-day course of either artesunate or quinine [Box 1].
However, there is limited information regarding the safety, efficacy, and adverse drug effects of the newer ACTs in pregnant women, as most trials in the past have excluded this subset of the population. This study  was carried out to address this issue.
| Key Results|| |
- Cure rates in the four groups:Overall cure rates at day 63 were
- 94.8% in the artemether–lumefantrine group,
- 98.5% in the amodiaquine–artesunate group,
- 99.2% in the dihydroartemisinin–piperaquine group, and
- 96.8% in the mefloquine–artesunate group.
- The cure rate was lower and the parasite clearance was slower in artemether–lumefantrine group as compared to other regimens
- The prevalence of placental malaria infection, mean birthweight, the incidence of low birthweight was similar across the treatment groups
- Adverse effects: There were ten adverse events probably related to the medication that were reported including anemia, upper abdominal pain, malaise, vomiting, headache, and general weakness. However, all the adverse events were completely reversible, and there was no significant difference in the incidence of adverse events across different treatment groups.
There was higher incidence of asthenia, poor appetite, dizziness, nausea, and vomiting among women treated with mefloquine–artesunate or amodiaquine–artesunate.
The incidence of stillbirths, preterm labor, and congenital malformation was varied between 1.9%–2.8%, 3.4%–10.2%, and 0.8%–2% simultaneously, without any statistical difference across the groups.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
PREGACT Study Group, Pekyi D, Ampromfi AA, Tinto H, Traoré-Coulibaly M, Tahita MC, et al.
Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med 2016;374:913-27.